» Articles » PMID: 37337518

CAR T Cell Therapy: Remedies of Current Challenges in Design, Injection, Infiltration and Working

Overview
Specialty Pharmacology
Date 2023 Jun 20
PMID 37337518
Authors
Affiliations
Soon will be listed here.
Abstract

Chimeric antigen receptor (CAR) T cell therapy, as an innovative immunotherapy, plays a huge role in current cancer therapy. Although CAR T cell therapy has demonstrated therapeutic effects in some subtypes of B cell leukemia or lymphoma, there are many challenges that limit the therapeutic efficacy of CAR T cells in solid tumors. And how to efficiently transport CAR T cells to tumor tissues is a continuing concern for us. In this review, experiments have been extensively studied and compared. We finally compared the influence of different injection methods on therapeutic efficacy. We also carefully explored the difficulties of designing, homing, and working of CAR T cells, and ultimately came up with better solutions for each process to help CAR T cells reach tumor tissue more efficiently and quickly. These results will have significant implications for guiding CAR T cell therapy in cancer treatment.

Citing Articles

CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges.

Zhou Y, Wei S, Xu M, Wu X, Dou W, Li H Front Immunol. 2024; 15:1489649.

PMID: 39569202 PMC: 11576447. DOI: 10.3389/fimmu.2024.1489649.


Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia.

Bartoszewska E, Tota M, Kisielewska M, Skowron I, Sebastianka K, Stefaniak O Cells. 2024; 13(18.

PMID: 39329777 PMC: 11430486. DOI: 10.3390/cells13181596.


Immunotherapy for colorectal cancer.

Yu B, Kang J, Lei H, Li Z, Yang H, Zhang M Front Immunol. 2024; 15:1433315.

PMID: 39238638 PMC: 11375682. DOI: 10.3389/fimmu.2024.1433315.

References
1.
Iwahori K . Cytotoxic CD8 Lymphocytes in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1224:53-62. DOI: 10.1007/978-3-030-35723-8_4. View

2.
Song D, Ye Q, Poussin M, Harms G, Figini M, Powell Jr D . CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 2011; 119(3):696-706. DOI: 10.1182/blood-2011-03-344275. View

3.
Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D . Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2020; 10(3):999-1011. PMC: 7897944. DOI: 10.1002/cam4.3686. View

4.
Liu K, Wu L, Yuan S, Wu M, Xu Y, Sun Q . Structural basis of CXC chemokine receptor 2 activation and signalling. Nature. 2020; 585(7823):135-140. DOI: 10.1038/s41586-020-2492-5. View

5.
Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F . Cancer-cell-secreted CXCL11 promoted CD8 T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer. 2019; 7(1):42. PMC: 6371476. DOI: 10.1186/s40425-019-0511-6. View